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OBJECTIVES We compared survival in treatment strategies and determined risk factors for one-year
mortality for hypoplastic left heart syndrome (HLHS) using intention-to-treat analysis.
BACKGROUND Staged revision of the native heart and transplantation as treatments for HLHS have been
compared in treatment-received analyses, which can bias results.
METHODS Data on 231 infants with HLHS, born between 1989 and 1994 and intended for surgery,
were collected from four pediatric cardiac surgical centers. Status at last contact for survival
analysis and mortality at one year for risk factor analysis were the outcome measures.
RESULTS Survival curves showed improved survival for patients intended for transplantation over
patients intended for staged surgery. One-year survival was 61% for transplantation and 42%
for staged surgery (p , 0.01); five-year survival was 55% and 38%, respectively (p , 0.01).
Survival curves adjusted for preoperative differences were also significantly different (p ,
0.001). Waiting-list mortality accounted for 63% of first-year deaths in the transplantation
group. Mortality with stage 1 surgery accounted for 86% of that strategy’s first-year mortality.
Birth weight ,3 kg (odds ratio [OR] 2.4), highest creatinine $2 mg/dL (OR 4.7), restrictive
atrial septal defect (OR 2.7) and, in staged surgery, atresia of one (OR 4.2) or both (OR 11.0)
left-sided valves produced a higher risk for one-year mortality.
CONCLUSIONS Transplantation produced significantly higher survival at all ages up to seven years. Patients
with atresia of one or both valves do poorly in staged surgery and have significantly higher
survival with transplantation. This information may be useful in directing patients to the
better strategy for them. (J Am Coll Cardiol 2000;36:1178–85) © 2000 by the American
College of Cardiology
Hypoplastic left heart syndrome (HLHS) is a lethal con-
genital heart malformation, resulting in a 95% mortality in
the first month of life when untreated (1) and accounting for
22% of deaths from congenital heart disease in the first year
of life (2). Infant heart transplantation and a staged revision
of the native heart currently offer hope of survival for
children with this condition. Staged surgery is more com-
monly available, partly because of the limited number of
donor hearts of an appropriate size.
Survival analyses and risk factor analyses have been
performed for each strategy. Razzouk et al. (3) found a
seven-year survival of 70% for transplanted patients and
61% for all listed patients. For staged surgery, a five-year
survival of 30% to 71% has been found (4–7). The two
procedures have been compared by Bando (8) for 50
neonates with HLHS, by Starnes (9) for 35, and by Jacobs
et al. (10) for 323 patients with aortic atresia. Two studies
found transplantation to be superior, and one found staged
surgery to have better outcomes. However, two of these
(8,9) analyzed crossover patients with a treatment-received
analysis rather than with intention-to-treat analysis, a more
conservative analytic approach (11,12). Jacob’s study (10)
found some advantage of transplantation over staged surgery
in three-year follow-up by intention-to-treat analysis. Re-
ports vary regarding which preoperative variables increase
mortality risk for infants with HLHS (5–8,10,13–18). The
choice that offers the better chance of survival to these
infants remains unclear.
Four pediatric cardiac surgical centers have collaborated
to collect preprocedure and outcome data on consecutive
patients with HLHS born between 1989 and 1994. These
infants were admitted with the intention to perform either
heart transplantation or staged surgical reconstruction. We
used intention-to-treat analysis to understand how babies
intended for a strategy fare. Intention-to-treat analysis
informs the dilemma of which treatment to undertake, as
opposed to reporting the outcomes of surgery. We com-
pared long-term survival between the transplantation strat-
egy and the staged surgical strategy, determined risk factors
for one-year mortality in infants with HLHS and developed
a prediction equation to help direct patients to the optimal
strategy based on individual characteristics. Tailoring the
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treatment to minimize the risk of mortality could improve
survival for these children.
METHODS
Selection criteria. Hypoplastic left heart syndrome was
defined as normal segmental anatomy with mitral and/or
aortic atresia or stenosis and a left ventricle too small to
sustain the systemic circulation. Babies with HLHS born
between January 1, 1989, and December 31, 1993, of birth
weight $2 kg, 37 to 42 weeks gestation, and admitted to the
surgical center with the intention to perform surgery were
included. Hypoplastic left heart syndrome babies with other
cardiac malformations, including any anomalous pulmonary
venous return (n 5 9), transposition of the great arteries
(n 5 2), ventricular septal defect (n 5 23) or double outlet
right ventricle (RV) (n 5 18) were excluded. Patients with
noncardiac malformations and chromosomal abnormalities
(n 5 16) were also excluded.
Participating sites. These sites are Egleston Children’s
Hospital in Atlanta, Children’s Hospital in Boston, Loma
Linda University Children’s Hospital and St. Louis Chil-
dren’s Hospital. The Internal Review Board of each hospital
approved this study.
Subjects. All patients with HLHS were identified at each
site by hospital database search. Medical records of eligible
patients were reviewed by the principal investigator. Of 242
eligible patients (Fig. 1), 11 charts were not located (5%).
Abbreviations and Acronyms
ASD 5 atrial septal defect
HLHS 5 hypoplastic left heart syndrome
OR 5 odds ratio
ROC 5 relative operating characteristic
RV 5 right ventricle, right ventricular
TR 5 tricuspid regurgitation
Figure 1. Distribution of 242 patients with HLHS who met entry criteria.
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Survival analysis included 231 cases: 109 in the staged
surgical group and 122 in the transplantation group. Risk
factor analysis included 221 cases; 10 patients died in other
hospitals while waiting on a participating center’s transplant
list.
Statistical methods. INTENTION-TO-TREAT GROUPS.
Treatment path was determined as the original intent for
surgery. Infants listed for transplantation remained in that
strategy; patients who received stage 1, then transplantation,
remained in the staged surgical group. Patients were fol-
lowed to the last known physician encounter. Seven patients
listed for transplantation received staged surgery; six pa-
tients received a transplant after stage 1 (Fig. 1). Three
patients received retransplantation.
CENSORING. Patients lost to follow-up or known to be still
alive were censored. The Kaplan–Meier method of survival
analysis (19) was used to generate and adjust survival curves
using preoperative variables that differed between the treat-
ment groups. The Mantel–Haenszel log-rank test (11)
tested the equality of the survivor functions. The software
program used was STATA 5.0 (Stata Corp., College
Station, Texas).
Risk factor analysis methods. UNIVARIATE ANALYSIS.
One-year survival was the dependent variable to assess risk
factors for mortality. Variables tested by univariate logistic
regression (20) are presented in Tables 1 and 2. All variables
were tested for first-order interactions. Correlation between
explanatory variables was tested. P-values for tests of trend
were generated by the Pearson chi-square statistic (11).
MISSING DATA. Missing data were dealt with in two ways
(21,22): 1) for variables not entered into the logistic regres-
sion model, missing data were not substituted; 2) sensitivity
analysis was performed on three variables missing $20% of
data tested in the regression: aortic diameter, moderate-to-
severe tricuspid regurgitation (TR) and moderate-to-poor
RV function. Sensitivity analysis determines whether the
Table 1. Univariate Odds Ratios of Preoperative Variables for One-Year Mortality
Variable
Transplantation
p-value
Staged surgery
p Value% died
Odds
ratio* 95% CI‡ % died
Odds
ratio* 95% CI‡
Patient characteristics
Birth weight 3–5 kg 30 1.00 56 1.00
,3 kg 45 1.96 (0.83–4.59) 0.12 74 2.26 (0.86–5.97) 0.10
Male gender 34 1.00 56 1.00
Female 32 0.89 (0.38–2.05) 0.78 61 1.22 (0.52–2.86) 0.64
Insurance: None 100 —† 80 2.97 (0.58–15.17) 0.19
Medicaid 37 1.53 (0.66–3.50) 0.31 44 0.58 (0.24–1.37) 0.21
Private 28 1.00 57 1.00
Disease characteristics
Anatomic subtype
Aortic and mitral stenosis 34 1.00 32 1.00
Atresia of one valve 36 1.14 (0.49–2.69) 0.76 62 3.39 (1.22–9.43) 0.02
Aortic and mitral atresia 32 0.97 (0.44–2.16) 0.95 76 6.72 (2.39–18.92) , 0.001
Aortic diameter .2 mm 27 1.00 55 1.00
#2 mm 45 2.24 (0.88–5.72) 0.09 77 3.42 (1.32–8.88) 0.03
Little to no TR‡ 27 1.00 61 1.00
Moderate-severe 50 2.67 (0.89–8.01) 0.08 46 0.56 (0.17–1.79) 0.32
Good RV‡ function 23 1.00 62 1.00
Moderate-poor 45 2.86 (0.87–9.38) 0.08 61 0.94 (0.42–2.12) 0.89
Lowest pH .7.20 25 1.00 59 1.00
#7.20 44 2.32 (0.95–5.67) 0.07 63 1.41 (0.63–3.16) 0.71
Highest creatinine ,2 mg/dL 26 1.00 60 1.00
$2 mg/dL 65 5.18 (1.72–15.60) 0.01 71 1.98 (0.58–6.77) 0.43
Unrestricted ASD‡ 28 1.00 59 1.00
ASD‡ requiring septostomy 48 2.38 (0.97–5.83) 0.06 56 0.86 (0.22–3.43) 0.84
Treatment characteristics
No epinephrine 21 1.00 60 1.00
Any use 60 5.74 (1.45–22.64) 0.01 67 1.33 (0.37–4.76) 0.66
Diagnosis after birth 33 1.00 56 1.00
Prenatal diagnosis 38 1.25 (0.47–3.34) 0.66 64 1.36 (0.52–3.57) 0.54
Diagnosis before discharge 33 1.00 60 1.00
Home ever 38 1.20 (0.40–3.60) 0.75 50 0.65 (0.26–1.68) 0.38
Age at first surgery
Less than 8 days 67 8.00 (1.26–50.77) 0.03 56 0.90 (0.39–2.05) 0.80
8–30 days 20 1.00 0.01 trend 65 1.00 0.10 trend
Over 1 month 12 0.55 (0.17–1.82) 0.33 0 —†
*The odds ratio compares the mortality of those with the values to those without, within each treatment strategy. †Less than 5% of patients in category, not enough information
to evaluate odds. ‡Abbreviations: CI 5 confidence interval; TR 5 tricuspid regurgitation; RV 5 right ventricular; ASD 5 atrial septal defect.
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logistic regression model is sensitive to the way missing
values are included. Patients were divided into treatment
groups and missing variables were assigned normal or
abnormal values by group. Each permutation of normal/
abnormal assignment by treatment group for missing data
was tested for univariate association with mortality.
MULTIPLE REGRESSION ANALYSIS. A logistic regression
model (20) for the 221 admitted patients characterized the
preoperative factors that placed infants with HLHS at risk
for death at one year. The model included variables with
univariate p-values of #0.25 and was reduced using the
likelihood ratio test (20). The relative contribution of each
variable to the explained mortality risk was calculated using
z-scores.
MODEL ASSESSMENT TECHNIQUES. We assessed the model
for its discrimination, using the area under the relative
operating characteristic (ROC) curve; internal validity, us-
ing bootstrap resampling; and goodness-of-fit between the
model and the data, using the Hosmer–Lemeshow test.
These techniques are described in the Appendix.
RESULTS
Of 231 patients with HLHS, 111 (48%) had died by one
year. Forty-three percent of the deaths occurred in the
transplantation strategy and 57% in the staged surgical
strategy.
When preoperative characteristics of patients in the
treatment groups were compared (Table 1), three charac-
teristics were found to be significantly different. The rate of
moderate-to-severe TR on the initial echocardiogram (p 5
0.01) and preoperative atrial septostomy rate (p 5 0.002)
were higher for transplantation than for staged surgery.
Waiting time prior to surgery differed, with 7% in trans-
plantation and 68% in staged surgery receiving an operation
within a week of life (p , 0.001). All other characteristics
were similar.
Survival analysis. Transplantation generated a higher sur-
vival at all time points through seven years of follow-up
(Fig. 2) (p , 0.001). The transplantation strategy had an
unadjusted one-year survival of 61% and a five-year survival
of 55% (p , 0.01) (Table 3). Staged surgery had an
unadjusted one-year survival of 42% and a five-year survival
of 38% (p , 0.01). For staged surgery, median survival was
2.6 months; for transplantation, median survival was two
years. After adjusting the survival curves for the different
incidence of moderate-to-severe TR on the initial echocar-
diogram, one-year survival in the staged surgical arm re-
mained at 42%, while survival in the transplantation arm
improved to 70% (p 5 0.01). The rates of restrictive atrial
septal defect (ASD) and age at surgery were consequences of
the wait and were not included in the adjustment.
Predischarge mortality following stage 1 surgery repre-
sented 78% (49/63) of the one-year mortality for this
strategy (Fig. 3). Ninety-three percent of the five-year
mortality for staged surgery occurred in the first year. For
transplantation, preoperative mortality accounted for 63%
(30/48) of the one-year mortality, and 87% of the five-year
Figure 2. Survival curves for transplantation and staged surgery. Unad-
justed survival curves.
Table 2. Variables Specific to Transplantation
Variable Median Mean Range
Time on waiting list (days) 19 30 1–171
Recipient age at surgery (days) 26 37 5–183
Donor age (days) 138 207 1–1118
Donor weight (kg) 6.5 6.5 2.2–13.4
Graft ischemic time (min) 240 249 65–439
Variable
#yes/#with info
(%)
%
died
Odds
ratio
95%
Confidence
interval
p-
value
Identical Blood Type 15 1.00
Non-identical 16/83 (19%) 19 1.32 (0.32–5.46) 0.71
Donor weight #2*recipient 15 1.00
.2*recipient weight 45/85 (53%) 16 1.04 (0.32–3.41) 0.94
Donor CPR, none 20 1.00
any 41/81 (51%) 12 0.56 (0.16–1.87) 0.34
Donor ischemic time ,6 h 12 1.00
$6 h 16/83 (19%) 31 3.35 (0.92–12.17) 0.07
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mortality occurred in the first year. Longer listing time did
not increase five-year mortality (p 5 0.16). All surviving
infants on the transplant list had received a donor heart by
six months of age.
Treatment-received analysis was also performed on the
survival data (Table 3). Treatment-received analysis pro-
duced a larger difference between treatments, evidenced by
smaller p-values.
Survival curves stratified by center showed no difference
in outcomes for staged surgery (p 5 0.86). For transplan-
tation, a significant difference in mortality by center was
found (p 5 0.02). Institutions listing fewer patients tended
to have higher mortality rates.
Risk factor analysis. Univariate associations between pre-
operative characteristics and one-year mortality (Tables 1
and 2) show that valvar atresia was predictive of higher
one-year mortality in the staged surgical strategy but not in
transplantation (Fig. 4). One-year mortality for mitral and
aortic stenosis was 32%, for atresia of one valve 62% (OR
3.4, p 5 0.02) and for atresia of both valves 76% (OR 6.7,
p # 0.001). Aortic diameter #2 mm was associated with
higher one-year mortality in staged surgery. In the trans-
plant arm, a maximum preoperative creatinine of $2 mg/dL
or restrictive ASD requiring septostomy yielded a higher
one-year mortality. Use of epinephrine and age at surgery
#7 days were also significant in univariate analysis.
Sensitivity analysis on missing data showed that the
model was sensitive only to missing data for birth weight;
replacing missing birth weight as $3 kg did not change the
model, but replacement as ,3 kg caused birth weight to
drop from the model. The model with missing birth weight
as $3 kg is presented. Missing data substitutions for TR,
RV function and aortic diameter produced nonsignificant
results.
Multiple logistic regression (Table 4) showed that a birth
weight ,3 kg (OR 2.4, p 5 0.01), creatinine $2 mg/dL
(OR 4.7, p , 0.001) and atrial septostomy (OR 2.7, p 5
0.02) were significant risk factors for one-year mortality in
all patients (n 5 221). Atresia of one (OR 4.2, p 5 0.001)
or both valves (OR 11.0, p , 0.001) were significant risk
factors for staged surgical mortality but not for transplan-
tation. Figure 5 shows the relative contribution of each risk
factor to the explained risk. This model produced an area
under the ROC curve of 0.77 (95% CI 0.71–0.83) (Appen-
dix). The model generated an area under the ROC curve of
0.73 (95% CI 0.57–0.78) for transplantation and 0.75 (95%
CI 0.60–0.80) for staged surgery.
Table 4 includes the probability of mortality based on
individual patient characteristics using the logistic regres-
sion model. Any patient with HLHS having no risk factors
(birth weight 4 kg, creatinine ,2 mg/dL, no septostomy
and mitral stenosis and aortic stenosis) has an OR of 0.22,
and a probability of one-year mortality of 18%. A patient
with HLHS having a creatinine , 2 mg/dL who received
staged surgery with mitral atresia and aortic atresia, a birth
weight of 4 kg and no septostomy has an OR of one-year
Figure 3. The timing of mortality in each strategy. The difference in
mortality is significant for preoperative, one-year and five-year mortality:
*p , 0.001, †p , 0.01.
Figure 4. Comparison of one-year mortality rates by valvar atresia. Trans-
plantation had a lower mortality for atresia of one or both left-sided valves
than staged surgery does; differences are significant at the p , 0.05 level.
Table 3. One- and Five-Year Survival by Treatment Path: Intention-to-Treat Versus
Treatment-Received Analysis
Analysis Transplantation Staged surgery p-value
Intention-to-treat n 5 122 n 5 109
Preoperative survival, % 75 98 , 0.001
1-year survival, % 61 42 0.005
5-year survival, % 55 38 0.009
Treatment received n 5 114 n 5 117
1-year survival, % 63 41 0.001
5-year survival, % 57 37 0.002
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mortality of 2.39 and a probability of 71%. A similar
transplanted patient would have an OR of 0.22, and a
probability of one-year mortality of 18%.
DISCUSSION
This analysis compares the staged surgical strategy to the
transplantation strategy, by survival curves and risk factors
for mortality, for 231 infants with HLHS at four pediatric
cardiac surgical centers from 1989 to 1994. Babies listed for
transplantation had a significantly higher survival than those
babies intended for staged surgery at one and five years (p ,
0.01). Four risk factors for one-year mortality were impor-
tant for infants with HLHS: birth weight ,3 kg, maximum
creatinine $2 mg/dL, atrial septostomy and atresia of one
or both left-sided valves in the staged surgical approach.
The difference in survival is not due to systematic,
case-mix differences or selection bias. Children with HLHS
placed in each strategy were similar, except for the initial
rate of moderate-to-severe TR and the consequences of the
surgical wait (atrial septostomy rate, preoperative mortality
rate) (Table 1). Adjusting for moderate-to-severe TR in-
creased the survival difference. The difference in survival is
not due to bias introduced by missing data. When variables
with large amounts of missing data were assigned normal or
abnormal values, no univariate relationship between one-
year mortality and TR, RV function, or aortic diameter
existed.
Nearly all of the mortality for both paths occurred in the
first year of life (Fig. 3). For patients who survived the first
year, approximately 90% in each strategy survived to age
five. Mortality after stage 1 tended to occur in-hospital.
Waiting-list mortality dominated the transplantation arm’s
first-year mortality.
These survival outcomes in this cohort of patients are not
the best reported outcomes from 1989 to 1993 for either
transplantation or staged surgery. The results are likely to be
more representative of the outcomes most children with
HLHS experienced. Such information is valuable for phy-
sicians discussing options and preparing families for the
survival potential of their child with HLHS.
Comparison to risk factor analyses in the literature.
Prior studies of preoperative risk factors for mortality in
each treatment strategy have used case numbers ranging
from 20 to over 200. Restrictive ASD or failed balloon
septostomy, nonidentical blood type and age at transplan-
tation have been important for the transplant group (13–
15). For the staged surgical approach, some centers, but not
all, have found aortic diameter #2 mm, atresia of both
mitral and aortic valves, preoperative acidosis, age .1
months at operation, earlier year of operation, obstruction to
pulmonary venous return, noncardiac congenital conditions
and weight ,3 kg to predict a higher risk of death
(5–8,16–18). Infants with aortic atresia had increased
three-year mortality risk for lower birth weight, noncardiac
anomalies, intention not to treat and staged surgical path
(10).
A high preoperative creatinine level and a restrictive ASD
increase mortality in transplantation by univariate analysis
(Table 1). Creatinine’s effect on transplantation survival
conceivably reflects the nephrotoxicity of some immunosup-
pressives. The need for atrial septostomy could be a proxy
measure for increased waiting time and may be subject to
practice variations. This study found no effect of noniden-
tical blood type or age over one month at transplantation for
the transplant group, and no effect of preoperative acidosis,
Figure 5. Relative contribution of each risk factor to the explained
one-year mortality risk. This pie graph shows that the increased mortality
encountered with aortic and mitral atresia in staged surgery accounts for
.50% of the explained mortality risk in patients with HLHS.
Table 4. Multivariable Odds Ratios and Prediction Equation Coefficients for One-Year Mortality
Variable OR 95% CI p-value Code Coefficient
Birth weight ,3 kg 2.44 (1.23–4.84) 0.01 1 5 Yes 0.89
Creatinine $2 mg/dL 4.66 (2.05–10.61) , 0.001 1 5 Yes 1.54
Atrial septostomy 2.69 (1.19–6.09) 0.02 1 5 Yes 0.99
Anatomic subtype
In staged surgery only
One-valve atresia 4.23 (1.81–9.88) 0.001 1 5 Yes 1.44
Atresia of both valves 11.04 (4.63–26.33) , 0.001 1 5 Yes 2.40
Constant — — — — 21.53
1. To calculate the odds of one-year mortality: exp[constant 1 (coefficient1*birth-weight code) 1 (coefficient2*creatinine code)
1 (coefficient3*septostomy code) 1 (coefficient4*anatomic-subtype code)]. An HLHS patient with a creatinine $2 mg/dL,
mitral atresia/aortic stenosis who received staged surgery, birth weight 4 kg and no septostomy, has a mortality odds of exp[21.53
1 (0.89*0) 1 (1.54*1) 1 (0.99*0) 1 (1.44*1)] 5 4.26. 2. Probability 5 odds/(1 1 odds). The probability of one-year mortality
5 4.26/5.26 5 81%. 3. A similar transplanted patient (birth weight 4 kg, creatinine $ 2 mg/dL, no septostomy, and mitral
atresia/aortic stenosis) has an odds 5 exp[21.53 1 (0.89*0) 1 (1.54*1) 1 (0.99*0) 1 (1.44*0)] 5 1.01, and a probability of
one-year mortality 5 1.01/2.01 5 50%.
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aortic diameter or age at surgery for the staged group.
Obstruction to pulmonary venous return or noncardiac
congenital conditions were exclusions from the study. Of
note, prenatal diagnosis did not improve survival in this
population.
Study limitations. The limitations of this study include the
possibility of “center effects.” Center effects would apply if
centers had varying outcomes for each strategy and large-
volume centers overwhelmed the analysis. Only widely
disparate outcomes in survival are detectable in a four-center
analysis. Institutions listing fewer patients tended to have
higher mortality rates, possibly due to differences in listing
practices, to regional organ donation rates or to volume
effects. This effect can be better understood in a study
involving many more transplant centers. However, the
disparity in survival between centers for listed patients
supports our conclusion that survival for listed patients is
higher than survival for staged surgical patients. A center
with a high waiting-list mortality will lower the overall
survival for the transplantation strategy and so decrease the
difference in survival between transplantation and staged
surgery. If significance is achieved even when the curves are
conservatively weighted, the difference in survival is proba-
bly real and not due to statistical manipulations.
Although surgical mortality did not show a significant
difference in survival by time period, one-year mortality
rates may have improved for these strategies. Both strategies
have the potential for significant late mortality in adoles-
cence and adulthood.
Intention-to-treat analysis. Treatment-received analysis
(8,9) can, in the worst case, make one strategy look better
than it actually is and make the other strategy look worse.
Bando et al.’s report (8) of 50 babies with HLHS found an
18% transplant mortality and a 50% staged surgical mortal-
ity, but if all seven of the listed patients who received a stage
1 surgery died, patients seeking transplantation could have
expected only a 45% survival (10/22); patients intended for
the staged procedure would have a 64% survival (18/28) by
intention-to-treat analysis. An intention-to-treat approach,
performed here and by Jacobs et al. (10), yields a conserva-
tive comparison of survival. In this study, intention-to-treat
methods gave transplantation poorer results than the
treatment-received analysis did, and gave staged surgery
better results (Table 3). Treatment-received analysis wid-
ened the difference between treatments. Although the
survival difference between intention-to-treat and
treatment-received analysis in this study was not statistically
significant (p . 0.10), the higher crossover rate in other
studies could significantly bias results.
Intention-to-treat analysis also seeks to address a different
question than does treatment-received analysis. Treatment-
received analysis usually evaluates the outcomes of proce-
dures. With intention-to-treat methods, researchers seek to
understand outcomes for patients who choose a particular
treatment. It informs the initial treatment decision.
Conclusions. From 1989 to 1994, transplantation pro-
duced a significantly higher survival than staged surgery in
the treatment of HLHS at the participating centers. Babies
with HLHS having birth weights $3 kg, normal creatinine
levels, no need for atrial septostomy and mitral stenosis/
aortic stenosis tend to do relatively well in both treatment
paths. Patients with atresia of one or both valves are at
increased risk for one-year mortality in the staged surgery
strategy.
The multiple logistic regression model in Table 4 is a
useful tool for determining one-year mortality risk for
particular patients with HLHS. It can help inform the
choice between strategies and allow the comparison of
survival results over time or across centers by risk adjustment
of caseloads. Once risk adjustment can be securely achieved,
centers can undertake initiatives to improve outcomes for
babies with HLHS.
Implications. The low first-year survival for both arms has
two major implications: 1) if more donor hearts were
available and waiting-list mortality could be reduced, five-
year survival in the transplantation arm for HLHS could
approach 80% at major surgical centers; 2) improvements in
stage 1 mortality could make this strategy equally successful
as transplantation.
The higher transplantation survival implies that more
babies with HLHS should be listed for transplantation. The
outcome of such a policy on the local or national level must
be considered. Increasing the number of potential recipients
could create greater public awareness of the need for organ
donation and hence increase donations. Alternatively, if
more babies were listed with the current shortage of infant
donor hearts, proportionately fewer babies would receive a
transplant and waiting-list mortality would increase. A
practical solution to this dilemma is to recommend staged
surgery for babies likely to do well in that path and list for
transplantation babies at higher risk in staged surgery.
In our dataset, valvar atresia was the only differentiating
factor in choosing between transplantation and staged
surgery for HLHS. The higher one-year mortality in staged
surgery was due primarily to poorer survival in patients with
one- or two-valve atresia. Transplantation may improve
survival in these babies if a successful transplant program
with adequate organ donation is available. Attention to risk
factors for first-year mortality, perioperative care and strat-
egies for improving donor availability offer the potential for
improving survival in children with HLHS.
APPENDIX
RISK FACTOR MODEL ASSESSMENT
It is important to assess how well the multivariable model
produced by a particular dataset actually works. The ideal
assessment of a model should answer several questions: 1)
How well does the model discriminate between patients
who lived and patients who died? 2) How consistent is that
discrimination at different levels of sensitivity and specific-
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ity? 3) Are there patients for whom the risk factor model
predicts poorly? and 4) How well does it discriminate
between patients who lived or died in other datasets? We
addressed three of these four questions, using the area under
the ROC curve, bootstrap resampling and the Hosmer-
Lemeshow goodness-of-fit test.
The area under the ROC curve measures the ability of the
logistic regression model to discriminate on the basis of
survival (23). The graph plots the model’s ability to correctly
predict outcome at different levels of true positive rate
(sensitivity) and false positive rate (1-specificity). A value of
0.5 represents a worthless model that predicts outcome as
well as a coin toss would. A value of 1.0 represents a model
that will perfectly predict outcome every time. Our model
yielded an area under the ROC curve of 0.77, similar to
values for prediction equations in other fields.
Bootstrap resampling was performed for the area under
the ROC curve. Bootstrapping is a nearly unbiased method
of internal validation (24). Bootstrapping avoids the loss of
power inherent in the training- and testing-set method.
Bootstrap resampling derives an area under the ROC curve
for a subset, replaces that subset and chooses another subset;
1,000 iterations produce the mean and 95% confidence
interval.
The Hosmer-Lemeshow goodness-of-fit test (25) as-
sessed how well the model fit the data. A significant p-value
indicates an unsatisfactory fit of the model to the data. The
test calculated expected mortality for three categories of
predicted risk for each regression model and compared
expected to observed mortality in each category. A well-
parameterized model would predict equally well for each
risk subgroup. Predicted risk was close to observed risk for
low- and high-risk patients in our model.
A complete assessment of a logistic regression model also
requires external validation. The risk factors must be perti-
nent in other datasets as well. Performing this next step will
allow the secure application of this information to newborns
with HLHS.
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